This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schimke, I. Articles by Hetzer, R. Search for Related Content PubMed PubMed Citation Articles by Schimke, I. Articles by Hetzer, R.

Decreased oxidative stress in patients with idiopathic dilated cardiomyopathy one year after immunoglobulin adsorption

Ingolf Schimke, PhD^*, Johannes Müller, MD, Friedrich Priem, Ingrid Kruse^*, Birgit Schön^*, Julia Stein, Rudolf Kunze, PhD^||, Gerd Wallukat, PhD and Roland Hetzer, MD

^* Medizinische Klinik, Berlin, Germany
Institut für Laboratoriumsmedizin, Humboldt-Universität zu Berlin, Berlin, Germany
Deutsches Herzzentrum Berlin, Berlin, Germany
Max-Delbrück-Centrum Berlin, Berlin, Germany
^|| Affina GmbH, Berlin, Germany

View larger version (28K): [in a new window]   Figure 1 Prestudy (black columns) and one-year levels (white columns) of plasma markers for oxidative stress in patients with idiopathic dilated cardiomyopathy conventionally treated (nontreated, n = 15) and treated with immunoglobulin adsorption (treated, n = 16). Prestudy level versus one-year level: +p 0.05; ++p 0.001; nontreated versus treated: #p 0.1. (A) Thiobarbituric acid-reactive substances (TBARS); (B) lipid peroxides (LPO); (C) anti-oxidized low-density lipoprotein-autoantibodies (anti-oxLDL-AB); (D) thiol groups; (E) vitamin E (Vit. E).

View larger version (25K): [in a new window]   Figure 2 Relationships between markers of oxidative stress and clinical status and cardiac performance in the complete population of patients conventionally treated (solid diamonds) and those treated with immunoglobulin adsorption (open diamonds). (A) Anti-oxidized low density lipoprotein autoantibodies (anti-oxLDL-AB) versus left ventricular ejection fraction (LVEF) prior to the study. (B) Thiobarbituric acid-reactive substances (TBARS) versus New York Heart Association functional class one year after immunoadsorption. (C) Lipid peroxides (LPO) versus LVEF one year after immunoadsorption. Prestudy to one-year change of anti-oxLDL-AB (d anti-oxLDL-AB) versus change of (D) LVEF (d LVEF), and (E) LVIDs (d LVIDs).